Thus, this finding has important clinical implications since inactivating genomic alterations in STK11 result in primary resistance to PD-1 and PD-L1 blockade and docetaxel in patients with KRAS-mutated NSCLC [114, 115]. This evidence concerns the gene KRAS and non-small cell lung carcinoma.